Abstract

Cell apoptosis induction and metastasis suppression in human breast cancer cell, MDA-MB-231, were studied to assess the potential of Cirsium setidens extract (CSE) on breast cancer treatment. Cell viability and metastasis analysis using MDA-MB-231 confirmed CSE significantly inhibited the growth and proliferation of cancer cell without suppressing normal cell growth in the range of 0.25 to 0.5 mg/mL of CSE. To analyze the anticancer effect of CSE, the expressions of major genes related to in the apoptosis, including p53, AMPK-α, Bcl-2, and Bax were analyzed by reverse transcription-polymerase chain reaction. The expressions of AMPK-α, p53, and Bax increased by 45, 43, and 68%, respectively, while the expression of Bcl-2 decreased by 12%, showing that CSE treatment induced apoptosis of MDA-MB-231. The major compound of CSE was identified as rhoifolin, a type of flavone, through analysis using LC-MS/MS. Our findings confirmed that rhoifolin, known to possess a variety of significant biological activities, could be obtained from C. setidens and used as an effective natural compound to suppress breast cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call